Joint Formulary & PAD

Terazosin hydrochloride - Benign prostatic hyperplasia

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Tablets
Associated Icons :
R
SPC
Restrictions / Comments :
Important

Restricted for patients with renal or hepatic failure

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Terazosin hydrochloride
Indication :
Benign prostatic hyperplasia
Group Name :
Keywords :
BPH, LUTS, urinary tract symptoms, urinary frequency, urinary incontinence
Brand Names Include :
Hytrin
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Committee Recommendations (1)

Where an alpha blocker is indicated, the PCN recommend one of the following as a 1st-line treatment option
- Tamsulosin (modified release) – GREEN (NOTE - prescribe as generic capsules)
- Doxazosin (immediate release) – GREEN (NOTE - XL / modified release preparations are considered BLACK)

Alfuzosin is more costly and is therefore not recommended as a 1st-line option. (NOTE - prescribe generically)

Terazosin is reserved for patients with hepatic or renal failure since no dose adjustment is required in these patient groups

Other Indications

Below are listed other indications that Terazosin hydrochloride is used to treat.

  • No records returned.